You are here

  • Home
  • Online First
  • MenB (Bexsero) immunisation side effects in extremely premature infants (

Article Text

Article menu

other Versions

Download PDFPDF
PostScript
Letter
MenB (Bexsero) immunisation side effects in extremely premature infants (<28 weeks)
  1. Arindam Mukherjee1,
  2. Devdeep Mukherjee2,
  3. Azita Rajai3,
  4. Srividhya Senthil4,
  5. Ngozi Edi-osagie5
  1. 1 Department of Neonatology, St Marys Hospital, Central Manchester University Hospitals NHS Foundation Trust, University of Manchester, Manchester, UK
  2. 2 Department of Neonatology, St Marys Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
  3. 3 Department of Research and Innovation, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK
  4. 4 Department of Neonatology, St Marys Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
  5. 5 Department of Neonatology, St Marys Hospital, Central Manchester University Hospitals NHS Foundation Trust, University of Manchester, Manchester, UK
  1. Correspondence to Dr Arindam Mukherjee, Consultant Neonatologist and Honorary Senior Lecturer, Department of Neonatology, St Marys Hospital, Central Manchester University Hospitals NHS Foundation Trust; arindam.mukherjee{at}cmft.nhs.uk

https://doi.org/10.1136/archdischild-2017-314009

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    On 1 September 2015, the UK became the world’s first country to introduce a novel meningococcal B vaccine (Bexsero) into its national childhood immunisation programme. Bexsero is the only market authorised meningococcal B vaccine in the UK. Meningococcal B strains accounts for ~80% of all laboratory confirmed cases of invasive meningococcal disease (IMD) in England and Wales1. Bexsero is estimated to protect against 73%–88% of the meningococcal B strains causing invasive disease in England and Wales2

    After observing more instances of clinical instability in our immunised neonates following the introduction of the new …

    View Full Text

    Footnotes

    • Original reference: None

    • Handling editor Martin Ward Platt

    • Contributors AM conceived the project. SS and DM were responsible for the data collection. Statistical input by AR.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.